Tyrosinekinase domains of EGFR/HER3 inhibited by afatinib.
The main driver mutation in cancer is in the RAS gene cluster where RAS acts like a oncogene. Medicaments with ingrdients like the pan ERBB-inhibitor afatinib which binds in the tyrosine kinase domain of EGFR (red) and switches
proliferative signals off stopping further tumor growth.
Keywords: Color, 3D, Research, Biology, Biotechnology, General Medicine, Natural Science / Nature, Oncology, Mechanism of Action (MOA), Pathology
© biolution GmbH